Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)

NCT03235245 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT03235245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03235245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 30, 2018
Completion date
January 31, 2027
Enrollment
271 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv melanoma, unresectable stage iii melanoma